Riddhi Siddhi Gluco Biols Falls to 52-Week Low of Rs.448 Amidst Continued Downtrend

Recent Price Movement and Market Context

On 18 Dec 2025, Riddhi Siddhi Gluco Biols opened with a gap down of 2.42%, continuing its slide from previous sessions. The stock's intraday low reached Rs.448, representing a 3.34% decline during the trading day and setting a new 52-week low. Over the last three days, the stock has delivered a cumulative return of -7.39%, underperforming its sector by 2.39% today alone.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish trend. This contrasts with the broader market, where the Sensex opened flat and is trading marginally lower by 0.09% at 84,481.81 points. The Sensex remains close to its 52-week high of 86,159.02, just 1.99% away, supported by mid-cap gains of 0.05% in the BSE Mid Cap index.

Financial Performance and Growth Trends

Riddhi Siddhi Gluco Biols has experienced a challenging financial trajectory over recent years. The company’s net sales have shown a compound annual growth rate (CAGR) of -14.03% over the last five years, reflecting contraction rather than expansion. This long-term trend is compounded by recent quarterly results that have been negative for three consecutive quarters.

In the latest six-month period, the company reported a profit after tax (PAT) of Rs.24.29 crore, which has declined by 40.98% compared to the previous period. Quarterly net sales stood at Rs.32.10 crore, down by 34.36%, while profit before tax excluding other income (PBT less OI) was recorded at a loss of Rs.4.05 crore, a fall of 225.00%. These figures highlight the pressures on the company’s revenue generation and profitability.

Profitability and Debt Servicing Concerns

The company’s ability to service its debt remains under strain, with an average EBIT to interest ratio of -1.18, indicating that earnings before interest and tax are insufficient to cover interest expenses. This weak coverage ratio is a key factor in the company’s negative return on capital employed (ROCE), signalling inefficiencies in generating returns from its capital base.

Additionally, the company’s earnings before interest, tax, depreciation and amortisation (EBITDA) have been negative, contributing to a perception of elevated risk relative to its historical valuation levels. Over the past year, while the stock has delivered a return of -29.56%, the company’s profits have declined by 18.7%, underscoring the challenges faced in maintaining profitability.

Comparative Performance and Market Position

Riddhi Siddhi Gluco Biols has underperformed the broader market indices over multiple time frames. Its one-year return of -29.56% contrasts with the Sensex’s gain of 5.36% over the same period. Furthermore, the stock has lagged behind the BSE500 index in the last three years, one year, and three months, reflecting below-par performance both in the near and longer term.

The stock’s 52-week high was Rs.700, indicating a significant decline of approximately 36% from that peak to the current 52-week low of Rs.448. The company operates within the Trading & Distributors sector, where market dynamics and sectoral trends may also influence stock performance.

Shareholding and Market Capitalisation

The majority shareholding in Riddhi Siddhi Gluco Biols is held by promoters, indicating concentrated ownership. The company’s market capitalisation grade is rated at 4, reflecting its size within the Trading & Distributors sector. Despite the stock’s recent declines, the broader market environment remains relatively stable, with the Sensex trading above its 50-day moving average and maintaining a bullish technical stance.

While the stock’s recent performance has been subdued, it is important to note that the broader indices and mid-cap segments have shown resilience, suggesting sectoral and market-wide factors may be influencing individual stock trajectories differently.

Summary of Key Metrics

To summarise, Riddhi Siddhi Gluco Biols has recorded the following key data points:

• New 52-week low price: Rs.448


• Three-day cumulative return: -7.39%


• One-year return: -29.56%


• Latest six-month PAT: Rs.24.29 crore, down 40.98%


• Quarterly net sales: Rs.32.10 crore, down 34.36%


• Quarterly PBT less other income: Rs.-4.05 crore, down 225.00%


• EBIT to interest ratio (average): -1.18


• Negative EBITDA and ROCE

These figures collectively illustrate the pressures faced by the company in both revenue generation and profitability, contributing to the stock’s recent decline to its lowest level in a year.

Market Environment and Technical Indicators

Despite the stock’s downward trajectory, the broader market environment shows contrasting signals. The Sensex remains close to its 52-week high and trades above key moving averages, supported by gains in mid-cap stocks. This divergence highlights the stock-specific factors impacting Riddhi Siddhi Gluco Biols, as opposed to broader market weakness.

Technically, the stock’s position below all major moving averages suggests continued pressure, with no immediate signs of reversal based on these indicators. The gap down opening and intraday lows reinforce the cautious sentiment prevailing among market participants.

Conclusion

Riddhi Siddhi Gluco Biols’ fall to a 52-week low of Rs.448 reflects a combination of subdued financial performance, weak profitability metrics, and technical pressures. The company’s declining sales, negative earnings trends, and challenges in servicing debt have contributed to this position. While the broader market maintains a relatively stable and bullish stance, the stock’s performance remains subdued within its sector and against market benchmarks.

Investors and market observers will continue to monitor the stock’s trajectory in the context of these financial and technical factors.

Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Start Saving Now →